ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate…
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology…
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from…
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in…
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product…
ANN ARBOR, Mich.--(BUSINESS WIRE)--NSF, the leading global public health and safety organization, today announced the appointment of Dean Bergy and…
- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility…
Agreements Support the Upcoming Launch of VEVYE®NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that…
PillSafe® protects the patient with a patented, innovative pill distribution control system that improves dosage safety, prevents prescription drug misuse,…
NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh…